Neurocrine Biosciences, NBI-567, NBI-1117567, Alzheimer’s disease, Phase 2 clinical trial, cognitive impairment, muscarinic agonist

San Diego, California, U.S., October 20, 2026 Neurocrine Biosciences has initiated a Phase 2 clinical study evaluating its investigational...